Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

C. Evangelisti, F. Ricci, P. Tazzari, G. Tabellini, M. Battistelli, E. Falcieri, F. Chiarini, R. Bortul, F. Melchionda, P. Pagliaro, A. Pession, J. A. McCubrey, A. M. Martelli

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

The mammalian Target Of Rapamycin (mTOR) serine/threonine kinase belongs to two multi-protein complexes, referred to as mTORC1 and mTORC2. mTOR-generated signals have critical roles in leukemic cell biology by controlling mRNA translation of genes that promote proliferation and survival. However, allosteric inhibition of mTORC1 by rapamycin has only modest effects in T-cell acute lymphoblastic leukemia (T-ALL). Recently, ATP-competitive inhibitors specific for the mTOR kinase active site have been developed. In this study, we have explored the therapeutic potential of active-site mTOR inhibitors against both T-ALL cell lines and primary samples from T-ALL patients displaying activation of mTORC1 and mTORC2. The inhibitors affected T-ALL cell viability by inducing cell-cycle arrest in G 0 /G 1 phase, apoptosis and autophagy. Western blot analysis demonstrated a Ser 473 Akt dephosphorylation (indicative of mTORC2 inhibition) and a dephosphorylation of mTORC1 downstream targets. Unlike rapamycin, we found a marked inhibition of mRNA translation in T-ALL cell lines treated with active-site mTOR inhibitors. The inhibitors strongly synergized with both vincristine and the Bcl-2 inhibitor, ABT-263. Remarkably, the drugs targeted a putative leukemia-initiating cell sub-population (CD34 /CD7 /CD4 ) in patient samples. In conclusion, the inhibitors displayed remarkable anti-leukemic activity, which emphasizes their future development as clinical candidates for therapy in T-ALL.

Original languageEnglish
Pages (from-to)781-791
Number of pages11
JournalLeukemia
Volume25
Issue number5
DOIs
Publication statusPublished - May 2011

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Sirolimus
Catalytic Domain
Protein Biosynthesis
Cell Line
Protein-Serine-Threonine Kinases
Autophagy
Vincristine
Cell Cycle Checkpoints
TOR complex 2
mechanistic target of rapamycin complex 1
Cell Biology
Cell Survival
Leukemia
Phosphotransferases
Adenosine Triphosphate
Western Blotting
Apoptosis
Survival
Therapeutics

Keywords

  • active site inhibitors
  • Acute lymphoblastic leukemia
  • mTOR
  • targeted therapy
  • translation

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Evangelisti, C., Ricci, F., Tazzari, P., Tabellini, G., Battistelli, M., Falcieri, E., ... Martelli, A. M. (2011). Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. Leukemia, 25(5), 781-791. https://doi.org/10.1038/leu.2011.20

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. / Evangelisti, C.; Ricci, F.; Tazzari, P.; Tabellini, G.; Battistelli, M.; Falcieri, E.; Chiarini, F.; Bortul, R.; Melchionda, F.; Pagliaro, P.; Pession, A.; McCubrey, J. A.; Martelli, A. M.

In: Leukemia, Vol. 25, No. 5, 05.2011, p. 781-791.

Research output: Contribution to journalArticle

Evangelisti, C, Ricci, F, Tazzari, P, Tabellini, G, Battistelli, M, Falcieri, E, Chiarini, F, Bortul, R, Melchionda, F, Pagliaro, P, Pession, A, McCubrey, JA & Martelli, AM 2011, 'Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia', Leukemia, vol. 25, no. 5, pp. 781-791. https://doi.org/10.1038/leu.2011.20
Evangelisti, C. ; Ricci, F. ; Tazzari, P. ; Tabellini, G. ; Battistelli, M. ; Falcieri, E. ; Chiarini, F. ; Bortul, R. ; Melchionda, F. ; Pagliaro, P. ; Pession, A. ; McCubrey, J. A. ; Martelli, A. M. / Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. In: Leukemia. 2011 ; Vol. 25, No. 5. pp. 781-791.
@article{29137aa97ec04e7c82a8fb2b04132919,
title = "Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia",
abstract = "The mammalian Target Of Rapamycin (mTOR) serine/threonine kinase belongs to two multi-protein complexes, referred to as mTORC1 and mTORC2. mTOR-generated signals have critical roles in leukemic cell biology by controlling mRNA translation of genes that promote proliferation and survival. However, allosteric inhibition of mTORC1 by rapamycin has only modest effects in T-cell acute lymphoblastic leukemia (T-ALL). Recently, ATP-competitive inhibitors specific for the mTOR kinase active site have been developed. In this study, we have explored the therapeutic potential of active-site mTOR inhibitors against both T-ALL cell lines and primary samples from T-ALL patients displaying activation of mTORC1 and mTORC2. The inhibitors affected T-ALL cell viability by inducing cell-cycle arrest in G 0 /G 1 phase, apoptosis and autophagy. Western blot analysis demonstrated a Ser 473 Akt dephosphorylation (indicative of mTORC2 inhibition) and a dephosphorylation of mTORC1 downstream targets. Unlike rapamycin, we found a marked inhibition of mRNA translation in T-ALL cell lines treated with active-site mTOR inhibitors. The inhibitors strongly synergized with both vincristine and the Bcl-2 inhibitor, ABT-263. Remarkably, the drugs targeted a putative leukemia-initiating cell sub-population (CD34 /CD7 /CD4 ) in patient samples. In conclusion, the inhibitors displayed remarkable anti-leukemic activity, which emphasizes their future development as clinical candidates for therapy in T-ALL.",
keywords = "active site inhibitors, Acute lymphoblastic leukemia, mTOR, targeted therapy, translation",
author = "C. Evangelisti and F. Ricci and P. Tazzari and G. Tabellini and M. Battistelli and E. Falcieri and F. Chiarini and R. Bortul and F. Melchionda and P. Pagliaro and A. Pession and McCubrey, {J. A.} and Martelli, {A. M.}",
year = "2011",
month = "5",
doi = "10.1038/leu.2011.20",
language = "English",
volume = "25",
pages = "781--791",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia

AU - Evangelisti, C.

AU - Ricci, F.

AU - Tazzari, P.

AU - Tabellini, G.

AU - Battistelli, M.

AU - Falcieri, E.

AU - Chiarini, F.

AU - Bortul, R.

AU - Melchionda, F.

AU - Pagliaro, P.

AU - Pession, A.

AU - McCubrey, J. A.

AU - Martelli, A. M.

PY - 2011/5

Y1 - 2011/5

N2 - The mammalian Target Of Rapamycin (mTOR) serine/threonine kinase belongs to two multi-protein complexes, referred to as mTORC1 and mTORC2. mTOR-generated signals have critical roles in leukemic cell biology by controlling mRNA translation of genes that promote proliferation and survival. However, allosteric inhibition of mTORC1 by rapamycin has only modest effects in T-cell acute lymphoblastic leukemia (T-ALL). Recently, ATP-competitive inhibitors specific for the mTOR kinase active site have been developed. In this study, we have explored the therapeutic potential of active-site mTOR inhibitors against both T-ALL cell lines and primary samples from T-ALL patients displaying activation of mTORC1 and mTORC2. The inhibitors affected T-ALL cell viability by inducing cell-cycle arrest in G 0 /G 1 phase, apoptosis and autophagy. Western blot analysis demonstrated a Ser 473 Akt dephosphorylation (indicative of mTORC2 inhibition) and a dephosphorylation of mTORC1 downstream targets. Unlike rapamycin, we found a marked inhibition of mRNA translation in T-ALL cell lines treated with active-site mTOR inhibitors. The inhibitors strongly synergized with both vincristine and the Bcl-2 inhibitor, ABT-263. Remarkably, the drugs targeted a putative leukemia-initiating cell sub-population (CD34 /CD7 /CD4 ) in patient samples. In conclusion, the inhibitors displayed remarkable anti-leukemic activity, which emphasizes their future development as clinical candidates for therapy in T-ALL.

AB - The mammalian Target Of Rapamycin (mTOR) serine/threonine kinase belongs to two multi-protein complexes, referred to as mTORC1 and mTORC2. mTOR-generated signals have critical roles in leukemic cell biology by controlling mRNA translation of genes that promote proliferation and survival. However, allosteric inhibition of mTORC1 by rapamycin has only modest effects in T-cell acute lymphoblastic leukemia (T-ALL). Recently, ATP-competitive inhibitors specific for the mTOR kinase active site have been developed. In this study, we have explored the therapeutic potential of active-site mTOR inhibitors against both T-ALL cell lines and primary samples from T-ALL patients displaying activation of mTORC1 and mTORC2. The inhibitors affected T-ALL cell viability by inducing cell-cycle arrest in G 0 /G 1 phase, apoptosis and autophagy. Western blot analysis demonstrated a Ser 473 Akt dephosphorylation (indicative of mTORC2 inhibition) and a dephosphorylation of mTORC1 downstream targets. Unlike rapamycin, we found a marked inhibition of mRNA translation in T-ALL cell lines treated with active-site mTOR inhibitors. The inhibitors strongly synergized with both vincristine and the Bcl-2 inhibitor, ABT-263. Remarkably, the drugs targeted a putative leukemia-initiating cell sub-population (CD34 /CD7 /CD4 ) in patient samples. In conclusion, the inhibitors displayed remarkable anti-leukemic activity, which emphasizes their future development as clinical candidates for therapy in T-ALL.

KW - active site inhibitors

KW - Acute lymphoblastic leukemia

KW - mTOR

KW - targeted therapy

KW - translation

UR - http://www.scopus.com/inward/record.url?scp=79955818156&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955818156&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.20

DO - 10.1038/leu.2011.20

M3 - Article

VL - 25

SP - 781

EP - 791

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 5

ER -